Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that will focus on developing a cell therapy product manufacturing platform. The JV will leverage a ...

Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

A court ruling has paved the way for South African pharmaceutical manufacturer Eurolab to continue producing and selling its ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance ...

Astellas also revealed today that it is terminating the development of ASP2390, a DNA vaccine for house dust mite-induced allergic rhinitis, and GITR agonist antibody ASP1951 for cancer – both ...

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) saw a significant increase in short interest in February. As of February 28th, there was short interest totalling 57,000 shares ...

Astellas Pharma Inc. is setting up a joint venture with Yaskawa Electric Corp. to develop a new cell production platform ...

"We appreciate the Chinese government's strong commitment to deepening reforms and expanding high-standard opening-up, with a ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a ...

NORTHBROOK, Ill., Feb. 27, 2025 /PRNewswire/ -- Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas"), and MBC BioLabs, a premier launchpad for ...

Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that will focus on developing a cell therapy product manufacturing platform. The JV will leverage a ...